Patents by Inventor Ki Moon Park

Ki Moon Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11827696
    Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: November 28, 2023
    Assignee: Sung Kyun Biotech Co., Ltd.
    Inventors: Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
  • Patent number: 11746146
    Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: September 5, 2023
    Assignee: SUNG KYUN BIOTECH CO., LTD.
    Inventors: Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
  • Patent number: 11732035
    Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: August 22, 2023
    Assignee: Sung Kyun Biotech Co., Ltd.
    Inventors: Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
  • Patent number: 11498945
    Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: November 15, 2022
    Assignee: Sung Kyun Biotech Co., Ltd.
    Inventors: Kyeong-Nam Yu, Eun-Yi Cho, Seung-Hee Chang, Seon-Hee Kim, Hyun-Suk Kim, Ki-Moon Park
  • Publication number: 20220106369
    Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: SUNG KYUN BIOTECH CO., LTD.
    Inventors: Kyeong-Nam YU, Eun-Yi CHO, Seung-Hee CHANG, Seon-Hee KIM, Hyun-Suk KIM, Ki-Moon PARK
  • Publication number: 20220106368
    Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
    Type: Application
    Filed: December 16, 2021
    Publication date: April 7, 2022
    Applicant: SUNG KYUN BIOTECH CO., LTD.
    Inventors: Kyeong-Nam YU, Eun-Yi CHO, Seung-Hee CHANG, Seon-Hee KIM, Hyun-Suk KIM, Ki-Moon PARK
  • Publication number: 20200010518
    Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.
    Type: Application
    Filed: November 28, 2017
    Publication date: January 9, 2020
    Applicant: SUNG KYUN BIOTECH CO., LTD.
    Inventors: Kyeong-Nam YU, Eun-Yi CHO, Seung-Hee CHANG, Seon-Hee KIM, Hyun-Suk KIM, Ki-Moon PARK
  • Publication number: 20150157675
    Abstract: The present invention relates to a Eupatorium spp. extract having anti-obesity effects as a result of decreasing adipocytes and increasing osteoblasts, as well as the effects of preventing bone disease or fractures by increasing osteoblasts and of preventing osteoporosis by decreasing adipocytes and increasing osteoblasts by the same proportion in mesenchymal stem cells. DCM fraction layers of a Eupatorium spp. stem extract collected on a monthly basis and Eupatorium spp. stem extract collected only in September may inhibit the activity of PPAR?, AP2, CD36, adiponectin C/EBP?, and LPL, which serve as significant factors for adipocyte differentiation in C3H10T1/2 cells and primary mesenchymal stem cells, which are pluripotent stem cell lines, and may increase the activity of ALP, osterix, CO1I and RUNX2, which serve as significant factors for osteoblast differentiation. The Eupatorium spp.
    Type: Application
    Filed: April 2, 2012
    Publication date: June 11, 2015
    Applicants: SUNG KYUN BIOTECH CO., LTD., REPUBLIC OF KOREA (MANAGEMENT:RURAL DEVELOPMENT ADMINISTRATION)
    Inventors: Hyun Seok Kim, Ki Moon Park, Min Ji Kim, Youngmin Lee, Haeng Ran Kim, Kang Jin Cho